A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Clinical trial NCT02973737 · UNKNOWN
Trial details
- NCT number
- NCT02973737
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-20
- Primary completion
- 2023-06-01
- Enrollment
- 279
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.